Idera Pharmaceuticals, Inc.
IDRA
NASDAQ0.38
Idera Pharmaceuticals, Inc.
NASDAQ:IDRA
RECENT
PRICE
0.38
P/E
RATIO
-0.92
(PEG:- -)
P/E RATIO
RELATIVE
TO S&P
-0.05
DIV
YLD
0.00%
High:
Low:
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Legends
Stock price
1.39 Beta (1.0 Market)
0
0
0
0
0
0
0
0
0
% total return 09/22:
Stock
S&P
1y.
0
0
3y.
0
0
5y.
0
0
0
Percent shares traded:
0
0
0
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
TTM
Fiscal year
1.17
(7.95)
1.21
- -
3.01
(4.98)
(6.56)
- -
9.31
0.53
8.18
- -
11.79
2.58
(5.37)
- -
5.13
(5.72)
(6.25)
- -
0.02
(6.89)
(5.56)
- -
0.01
(5.57)
(5.76)
0.17
0.01
(3.32)
(3.12)
0.19
0.01
(3.73)
(3.13)
0.08
0.02
(3.38)
(3.04)
- -
1.02
(2.41)
(1.79)
- -
0.05
(3.35)
(2.82)
- -
0.02
(2.25)
(1.95)
- -
0.05
(1.98)
(1.56)
- -
- -
(3.33)
(1.00)
- -
- -
2.90
(0.73)
- -
- -
(0.42)
(0.38)
- -
Revenue per share
Earnings per share
Free Cash Flow per sh
Dividends per share
0.04
5.89
0.62
2.91
0.14
7.83
0.04
11.31
0.03
10.53
0.01
3.48
- -
1.92
0.00
5.91
0.11
4.19
0.05
5.81
0.03
6.48
0.01
5.47
0.00
2.41
0.00
(0.39)
0.00
(2.70)
- -
0.87
- -
0.60
CAPEX per share
Book Value per share
2
3
3
3
3
3
3
5
10
14
16
20
27
29
34
34
52
Comm.Shares outs.(m)
(4.3)
(0.2)
- -
(14.2)
(0.8)
- -
174.0
8.1
- -
19.9
0.3
- -
(5.8)
(0.3)
- -
(2.5)
(0.2)
- -
(1.7)
(0.1)
1.8%
(3.3)
(0.2)
1.8%
(7.4)
(0.4)
0.3%
(8.7)
(0.4)
- -
(6.2)
(0.3)
- -
(4.7)
(0.2)
- -
(5.0)
(0.2)
- -
(1.4)
(0.1)
- -
(0.7)
(0.0)
- -
0.7
0.0
- -
(0.9)
(0.0)
- -
Avg. annual P/E ratio
P/E relative to S&P500
Avg. annual div. yield
Capital Structure (31/3/22 | Q1)
Total liabilities
$4 m.
Total assets
$30 m.
Long-term debt
$0 m.
Cash and equiv.
$28 m.
Goodwill - -
Retained earnings $(740) m.
Common stock 53 m. shares
Market Capitalisation
$20 m. (as of 25/9/22)
0
(48,783.0)%
0
(39,021.6)%
0
(38,657.4)%
0
(53,084.9)%
0
(19,616.9)%
16
(239.3)%
1
(7,368.8)%
1
(9,207.9)%
1
(3,181.4)%
- -
(Infinity)%
- -
(Infinity)%
- -
(Infinity)%
Revenue (m)
Operating margin
0
(24)
0
(19)
0
(18)
0
(39)
0
(49)
1
(38)
1
(66)
0
(60)
0
(57)
0
(113)
0
98
0
(22)
Depreciation (m)
Net profit (m)
- -
(44,860.4)%
- -
(37,725.5)%
- -
(38,778.7)%
- -
(52,934.2)%
- -
(19,500.0)%
- -
(237.0)%
- -
(7,315.3)%
- -
(9,045.5)%
- -
(3,903.0)%
- -
(Infinity)%
- -
Infinity%
- -
(Infinity)%
Income tax rate
Net profit margin
19
- -
12
6
- -
7
26
- -
32
35
1
43
56
1
84
102
0
103
107
- -
108
64
- -
64
(8)
- -
(11)
34
- -
(91)
29
1
29
26
0
26
Working capital (m)
Long-term debt (m)
Equity (m)
(121.9)%
(92.9)%
(197.7)%
(287.5)%
(177.8)%
(290.3)%
(56.2)%
(49.4)%
(56.2)%
(87.1)%
(75.1)%
(89.0)%
(56.7)%
(52.5)%
(58.1)%
(36.9)%
(33.8)%
(37.1)%
(60.9)%
(55.7)%
(61.3)%
(93.5)%
(82.0)%
(93.6)%
804.1%
(119.0)%
506.0%
(103.7)%
(86.5)%
123.6%
(92.2)%
(79.4)%
333.0%
(77.8)%
(68.0)%
(84.5)%
ROIC
Return on capital
Return on equity
Working Capital
2019
2020
2021
Cash assets
43
36
35
Receivables
- -
- -
- -
Inventory
- -
- -
- -
Other
3
4
1
Current assets
46
41
34
Acc. Payable
0
0
1
Debt due
0
0
0
Other
54
7
4
Current liab.
55
7
5
100.0%
- -
103.0%
- -
105.8%
- -
102.1%
- -
100.0%
- -
100.0%
- -
100.0%
- -
100.0%
- -
100.0%
- -
100.0%
- -
100.0%
0.6%
100.0%
- -
Plowback ratio
Div.&Repurch. to FCF
Idera Pharmaceuticals, Inc. (US) started trading on January 4, 1996 (cik: 0000861838), operates in the Healthcare sector (Biotechnology industry), has 13 full-time employees, and is led by Mr. Vincent Milano. Idera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for rare disease indications in the United States. It offers Tilsotolimod (IMO-2125), a synthetic phosphorothioate oligonucleotide that acts as a direct agonist of TLR9 to stimulate the immune systems and for treating solid tumors, squamous cell carcinoma of the head and neck, and colorectal cancer. The company has a collaboration agreement with Bristol-Meyers Squibb. Idera Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Exton, Pennsylvania.
Annual rates
(avg rate of change)
Past
5 y.
Past
10 y.
Revenues
- -
- -
Cash flow
-17.99%
10.82%
Earnings
-25.65%
8.97%
Dividends
- -
- -
Book value
106.51%
107.77%
Insider trading
Type
Shares
Date
Soland Daniel B
Award
66,500
07/06/22
Lim Bryant David
Award
66,500
07/06/22
Kirby John J.
Award
66,500
07/06/22
Milano Vincent
Award
124,000
07/06/22
Dougherty Michael R
Award
50,086
07/01/22
Fiscal Year Ends
Quarterly Revenue (m)
Full fiscal year
I
II
III
IV
2020
- -
- -
- -
- -
- -
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
Fiscal Year Ends
Earnings per share
Full fiscal year
I
II
III
IV
2020
0.26
(0.72)
(0.61)
(2.27)
-3.33
2021
3.42
(0.22)
(0.18)
(0.12)
2.90
2022
(0.08)
- -
- -
- -
- -
Fiscal Year Ends
Quarterly dividends paid
Full fiscal year
I
II
III
IV
2020
- -
- -
- -
- -
- -
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -